Continue reading this on our app for a better experience

Open in App
Floating Button
Home Capital Broker's Calls

Strategic review to determine if Q&M will rise again

Michelle Zhu
Michelle Zhu • 2 min read
Strategic review to determine if Q&M will rise again
SINGAPORE (March 6): Maybank Kim Eng Research has downgraded its rating on Q&M Dental from “buy” to “hold”, lowering its target price on the stock to 71 cents from $1 previously on the group’s FY16 core earnings miss.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (March 6): Maybank Kim Eng Research has downgraded its rating on Q&M Dental from “buy” to “hold”, lowering its target price on the stock to 71 cents from $1 previously on the group’s FY16 core earnings miss.

To recap, Q&M last Wednesday posted full year earnings of $28.3 million, which was more than double as compared to the previous financial year on a one-off gain from its spin-off of Aidite, the group’s manufacturing arm.

Core earnings, however, missed Maybank’s forecast by 12% due to higher-than-expected costs, amid integration of mergers and acquisitions (M&As) and spin-off of the group’s subsidiaries.

(See also: Q&M Dental full year earnings more than double to $28.3 mil on one-off gain)

The higher costs were due to losses incurred from the group’s medical segment; assets written off from the unsuccessful start-up of a new dental clinic; as well as a goodwill impairment of $4.1 million for businesses in Malaysia and Singapore, due to a weaker Malaysian ringgit and a premium paid for a Singapore M&A.

“On the positive side, core earnings grew by a commendable 23% YoY, after adjusting for various one-off items. To account for higher integration costs and earnings dilution from spin-off of two subsidiaries, we cut FY17-18E EPS by 19-28%,” shares analyst John Cheong in a Monday report.

Other key positives include healthy topline growth, a higher dividend, and a good performance delivered from Aidite after increasing its capacity.

Religare has been appointed to perform a strategic review of the group’s business, and Cheong believes the market’s anticipation of this could support Q&M’s share price going forward.

(See also: Q&M Dental Group undertakes strategic review of business)

“A positive outcome from the review could pose further upside to our target price,” he adds.

As at 11am, shares of Q&M are trading flat at 70 cents.

Highlights

Re test Testing QA Spotlight
1000th issue

Re test Testing QA Spotlight

×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.